PubRank

A J Demetris

Author PubWeight™ 467.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989 13.70
2 Cell migration, chimerism, and graft acceptance. Lancet 1992 12.24
3 The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 9.02
4 Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993 8.76
5 Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery 1991 5.92
6 Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994 5.54
7 Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 5.39
8 Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990 5.01
9 Liver transplantation (1). N Engl J Med 1989 4.53
10 Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology 1994 4.32
11 Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today 1993 4.29
12 Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 1990 4.18
13 Baboon-to-human liver transplantation. Lancet 1993 4.01
14 Systemic chimerism in human female recipients of male livers. Lancet 1992 3.63
15 Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation 1995 3.63
16 Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991 3.57
17 Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc 1987 3.55
18 Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014 3.43
19 Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med 1993 3.36
20 Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991 3.34
21 Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc 1990 3.29
22 Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010 3.29
23 Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron 1987 3.26
24 The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988 3.24
25 Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery 1990 3.18
26 Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol 1985 3.16
27 Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993 3.13
28 Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc 1987 3.11
29 Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992 2.98
30 Liver transplantation (2). N Engl J Med 1989 2.93
31 Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997 2.91
32 Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000 2.91
33 The lost chord: microchimerism and allograft survival. Immunol Today 1996 2.81
34 A review of adult and pediatric post-transplant liver pathology. Pathol Annu 1987 2.62
35 FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994 2.50
36 Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med 1994 2.48
37 FK 506 in clinical kidney transplantation. Transplant Proc 1991 2.29
38 Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc 1991 2.28
39 Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012 2.28
40 Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg 1995 2.25
41 Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992 2.20
42 Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA 1995 2.20
43 Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation 1993 2.17
44 Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation 1993 2.14
45 Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol 1990 2.11
46 One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc 1991 2.10
47 A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995 2.09
48 Pathology of human intestinal transplantation. Gastroenterology 1996 1.98
49 Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997 1.98
50 Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 1991 1.95
51 Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation 1993 1.94
52 Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999 1.93
53 Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc 1991 1.89
54 Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 1995 1.83
55 The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992 1.83
56 Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation 1985 1.75
57 Small intestinal transplantation in humans with or without the colon. Transplantation 1994 1.74
58 Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc 1993 1.72
59 The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996 1.71
60 Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005 1.70
61 Transplantation tolerance, microchimerism, and the two-way paradigm. Theor Med Bioeth 1998 1.67
62 Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation 1996 1.65
63 Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology 1999 1.64
64 Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol 1986 1.63
65 Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. Lancet 1992 1.61
66 Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant 2009 1.59
67 Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995 1.59
68 Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989 1.58
69 Weaning of immunosuppression in liver transplant recipients. Transplantation 1997 1.57
70 The biological basis of and strategies for clinical xenotransplantation. Immunol Rev 1994 1.56
71 Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation 2000 1.53
72 Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997 1.52
73 Drug development and testing in relation to cell migration and chimerism. Transplant Proc 1993 1.52
74 Split tolerance induced by orthotopic liver transplantation in mice. Transplantation 1994 1.52
75 "Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant 2013 1.52
76 Occurrence of cytomegalovirus hepatitis in liver transplant patients. J Med Virol 1988 1.50
77 Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology 1994 1.49
78 FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery 1991 1.49
79 Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. Transplantation 1995 1.45
80 Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 1992 1.45
81 Recurrent hepatic allograft injury in erythropoietic protoporphyria. Transplantation 1996 1.41
82 Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998 1.41
83 Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology 1990 1.38
84 Donor dendritic cell repopulation in recipients after rat-to-mouse bone-marrow transplantation. Lancet 1992 1.32
85 The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993 1.32
86 Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 1990 1.31
87 The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol 2000 1.31
88 A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology 1989 1.30
89 Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc 1994 1.29
90 Canine total orthotopic small bowel transplantation under FK 506. Transplant Proc 1991 1.29
91 Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000 1.27
92 Comparison of the small intestine after multivisceral transplantation with the small intestines transplanted with portal or caval drainage. Transplant Proc 1992 1.26
93 Liver transplantation: a 31-year perspective. Part III. Curr Probl Surg 1990 1.25
94 Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury. J Leukoc Biol 1992 1.25
95 Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes Cancer 1990 1.24
96 Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. Transplantation 1998 1.22
97 Donor bone marrow cell infusion without recipient cytoablation induces acceptance of rat islet allografts. Transplant Proc 1994 1.22
98 Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant 2013 1.22
99 Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997 1.22
100 Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet 1993 1.21
101 Donor species complement after liver xenotransplantation. The mechanism of protection from hyperacute rejection. Transplantation 1994 1.21
102 Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Hepatology 1998 1.20
103 Liver transplantation: a 31-year perspective. Part I. Curr Probl Surg 1990 1.20
104 Combined kidney/bone marrow transplantation--evidence of augmentation of chimerism. Transplantation 1995 1.19
105 Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver vs. heart allografts. Hepatology 1992 1.18
106 Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg Gynecol Obstet 1989 1.17
107 Nephropathy due to polyomavirus type BK. N Engl J Med 2000 1.16
108 A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. Clin Transplant 1994 1.15
109 A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc 1995 1.13
110 Transplantation for primary biliary cirrhosis. Gastroenterology 1988 1.12
111 Clinical intestinal transplantation: focus on complications. Transplant Proc 1992 1.11
112 Tacrolimus in renal transplantation. Transplant Proc 1996 1.10
113 Cytokine mRNA profiles in mouse orthotopic liver transplantation. Graft rejection is associated with augmented TH1 function. Transplantation 1995 1.10
114 Dendritic cell replacement in long-surviving liver and cardiac xenografts. Transplantation 1993 1.10
115 Functional cooperation of xenoproteins after hamster-to-rat liver transplantation: With particular reference to hamster C3 and secretory component for rat IgA. Xenotransplantation 1995 1.08
116 Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995 1.08
117 Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993 1.08
118 Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: with particular reference to chronic rejection. Liver Transpl 2000 1.07
119 Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation 1994 1.06
120 Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology 1996 1.06
121 Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. Am J Pathol 1993 1.06
122 Digital transplantation pathology: combining whole slide imaging, multiplex staining and automated image analysis. Am J Transplant 2011 1.05
123 Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol 1997 1.05
124 Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993 1.05
125 Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant 2008 1.05
126 The influence of donor and recipient strains in isolated small bowel transplantation in rats. Transplant Proc 1994 1.04
127 Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology 1992 1.04
128 Donor hematopoietic progenitor cells in nonmyeloablated rat recipients of allogeneic bone marrow and liver grafts. Transplantation 1999 1.04
129 Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc 1993 1.03
130 The systemic distribution of Epstein-Barr virus genomes in fatal post-transplantation lymphoproliferative disorders. An in situ hybridization study. Am J Pathol 1991 1.02
131 Intestinal transplantation in children under FK 506 immunosuppression. J Pediatr Surg 1993 1.02
132 Combined bone marrow and whole organ transplantation from the same donor. Transplant Proc 1994 1.02
133 Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. Transplant Proc 1991 1.01
134 Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. Transplant Proc 1995 1.00
135 Analysis of T lymphocytes infiltrating human hepatic allografts. Transplant Proc 1987 1.00
136 Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. J Natl Cancer Inst 2001 0.99
137 Mixed xenogeneic chimerism (mouse+rat-->mouse) to induce donor-specific tolerance to sequential or simultaneous islet xenografts. Transplantation 1994 0.99
138 Prospects of clinical xenotransplantation. Transplant Proc 1994 0.98
139 Composition of human islet cell preparations for transplantation. Acta Diabetol 1992 0.97
140 Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail 1997 0.97
141 Vascularized bone marrow transplantation in rats: evidence for amplification of hematolymphoid chimerism and freedom from graft-versus-host reaction. Transplant Proc 1995 0.97
142 Recognition of major histocompatibility complex antigens on cultured human biliary epithelial cells by alloreactive lymphocytes. Hepatology 1991 0.96
143 The effect of interleukin-6 (IL-6)/gp130 signalling on biliary epithelial cell growth, in vitro. Cytokine 2000 0.96
144 Indocyanine green elimination test in orthotopic liver recipients. Hepatology 1996 0.96
145 The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014 0.96
146 Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation 2000 0.95
147 Detection of replicative hepatitis C virus sequences in hepatocellular carcinoma. Am J Pathol 1992 0.95
148 The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation 1993 0.95
149 Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001 0.95
150 Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study. J Cancer Res Clin Oncol 2001 0.95
151 Neurilemmoma (schwannoma) of the facial nerve presenting as a parotid mass. Otolaryngol Head Neck Surg 1993 0.95
152 Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation 1997 0.95
153 Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. Transplant Proc 1996 0.95
154 Allogeneic orthotopic liver transplantation in mice: a preliminary study of rejection across well-defined MHC barriers. Transplant Proc 1991 0.95
155 Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Mod Pathol 1996 0.94
156 Adding value to liver (and allograft) biopsy evaluation using a combination of multiplex quantum dot immunostaining, high-resolution whole-slide digital imaging, and automated image analysis. Clin Liver Dis 2010 0.94
157 Multilineage amplification of graft-vs-host disease-resistant chimerism following rat vascularized bone marrow allotransplantation. Transplant Proc 1995 0.94
158 Propagation of lymphocytes infiltrating human liver allografts. Correlation with histologic diagnosis of rejection. Transplantation 1990 0.93
159 Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001 0.93
160 Nitric oxide synthesis serves to reduce hepatic damage during acute murine endotoxemia. Crit Care Med 1992 0.92
161 Clinical significance of renal allograft biopsies with "borderline changes," as defined in the Banff Schema. Transplantation 1997 0.92
162 Cause and timing of first allograft failure in orthotopic liver transplantation: a study of 177 consecutive patients. Hepatology 1991 0.91
163 Intrahepatic biliary strictures after liver transplantation. Radiology 1994 0.91
164 Explanation for loss of the HLA matching effect. Transplant Proc 1995 0.91
165 Tumor necrosis factor-alpha regulates in vivo nitric oxide synthesis and induces liver injury during endotoxemia. Hepatology 1994 0.91
166 Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992 0.91
167 Recurrent and de novo giant cell hepatitis after orthotopic liver transplantation. Am J Surg Pathol 1994 0.91
168 Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant 1997 0.90
169 Antibody deposition in liver allografts with chronic rejection. Transplant Proc 1987 0.90
170 Effects of preformed antibodies induced by whole blood transfusion on small bowel transplantation. Transplant Proc 1994 0.90
171 Double immunoenzyme staining method for analysis of tissue and blood lymphocyte subsets with monoclonal antibodies. Lab Invest 1987 0.90
172 Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc 1996 0.90
173 Chronic liver allograft rejection and obliterative arteriopathy: possible pathogenic mechanisms. Transplant Proc 1989 0.90
174 Cholangiocarcinoma and sclerosing cholangitis: clinical characteristics and effect on survival after liver transplantation. Transplant Proc 1993 0.89
175 Liver transplants contribute to their own success. Nat Med 1996 0.89
176 Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001 0.89
177 Acute obstructive cholangiopathy in interleukin-6 deficient mice: compensation by leukemia inhibitory factor (LIF) suggests importance of gp-130 signaling in the ductular reaction. Liver 2000 0.89
178 Multiphoton intravital microscopy of the transplanted mouse kidney. Am J Transplant 2011 0.89
179 Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2011 0.88
180 Hamster coagulation and serum proteins in rat recipients of hamster xenografts. Transplantation 1993 0.88
181 Transmission of fatal herpes simplex infection through renal transplantation. Transplantation 1988 0.88
182 Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant 2000 0.88
183 Graft-versus-host disease in fully allogeneic small bowel transplantation: incidence of the disease and strain combinations. Transplant Proc 1993 0.88
184 Participation of dendritic cells in vascular lesions of chronic rejection of human allografts. Lancet 1988 0.86
185 Central venulitis in liver allografts: considerations of differential diagnosis. Hepatology 2001 0.86
186 Nitric oxide and prostaglandins interact to prevent hepatic damage during murine endotoxemia. Am J Physiol 1994 0.86
187 Clonal characteristics of posttransplant lymphoproliferative disorders. Transplant Proc 1988 0.86
188 Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. Transplant Proc 1999 0.86
189 Immunopathology of cardiac transplant rejection. Curr Opin Cardiol 1995 0.86
190 Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998 0.86
191 Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994 0.85
192 Sequential analyses of the development of lymphoproliferative disorders in rats receiving cyclosporine. Transplantation 1984 0.85
193 Allograft outcomes in outbred mice. Am J Transplant 2013 0.85
194 Prognostic models in hepatocellular carcinoma (HCC) and statistical methodologies behind them. Curr Pharm Des 2007 0.84
195 A new protocol for the propagation of dendritic cells from rat bone marrow using recombinant GM-CSF, and their quantification using the mAb OX-62. J Immunol Methods 1995 0.84
196 Primary carcinoma of Stensen's duct: recognition and management with literature review. J Surg Oncol 1984 0.84
197 Role of splenectomy in human liver transplantation under modern-day immunosuppression. Dig Dis Sci 1998 0.84
198 The future of transplantation: with particular reference to chimerism and xenotransplantation. Transplant Proc 1997 0.83
199 Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection? Transpl Int 1988 0.83
200 Interferon-gamma induced expression of MHC antigens facilitates identification of donor cells in chimeric transplant recipients. Cell Transplant 1994 0.83
201 Peribiliary vascular diseases in rejected livers; computer-aided three-dimensional reconstruction and morphometry. Transplant Proc 1991 0.83
202 Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts. Circulation 1998 0.83
203 Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. Transplant Proc 1995 0.83
204 Interleukin-2 and interleukin-12 mediate distinct effector mechanisms of liver allograft rejection. Liver Transpl Surg 1997 0.83
205 Pathologist's perspective on liver needle biopsy size? J Hepatol 2003 0.83
206 A new liver perfusion and preservation system for transplantation research in large animals. J Invest Surg 1990 0.83
207 Effect in supralethally irradiated rats of granulocyte colony-stimulating factor and lisofylline on hematopoietic reconstitution by syngeneic bone marrow or whole organ passenger leukocytes. Transplantation 1997 0.83
208 A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996 0.83
209 Concanavalin A simultaneously primes liver hematopoietic and epithelial progenitor cells for parallel expansion during liver regeneration after partial hepatectomy in mice. Hepatology 2000 0.83
210 Tacrolimus nephrotoxicity after renal transplantation. Transplant Proc 1997 0.83
211 Liver transplant rejection: angiographic findings in 35 patients. AJR Am J Roentgenol 1987 0.83
212 Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year follow-up. Transplant Proc 2001 0.82
213 Heterogeneous immediate effects of partial left ventriculectomy on cardiac performance. Circulation 1998 0.82
214 Lack of susceptibility of baboons to infection with hepatitis B virus. Transplantation 1996 0.82
215 Mouse liver transplantation tolerance: the role of hepatocytes and nonparenchymal cells. Transplant Proc 1995 0.82
216 In vitro characterization of rat bone marrow-derived dendritic cells and their precursors. J Leukoc Biol 1996 0.82
217 Herpesvirus 6 variant A infection after heart transplantation with giant cell transformation in bile ductular and gastroduodenal epithelium. Am J Surg Pathol 1997 0.81
218 Heterogenous distribution of chimerism produced by rat organ and bone marrow allotransplantation. Transplantation 1996 0.81
219 Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc 1998 0.81
220 Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2 to 19 years follow-up. Transplant Proc 2001 0.81
221 Islet cell allotransplantation in diabetic patients. Histologic findings in four adults simultaneously receiving kidney or liver transplants. Am J Pathol 1992 0.81
222 Histologic monitoring of human small bowel allografts with clinical correlation. Transplant Proc 1992 0.81
223 Human liver xenotransplantation. Xeno 1993 0.81
224 Normotest and abnormal prothrombin in liver transplantation. Liver 1995 0.81
225 Attenuation of lethal graft-versus-host disease by inhibition of nitric oxide synthase. Transplantation 1997 0.81
226 Procurement of liver allografts from non-heart beating donors. Transplant Proc 1990 0.80
227 Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clin Transplant 1999 0.80
228 Autoimmune liver diseases. Recurrence after liver transplantation. Surg Clin North Am 1999 0.80
229 Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer 1993 0.80
230 Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg 1998 0.80
231 Microchimerism: inaccurate literature citations. Transplantation 1996 0.80
232 Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. Transplant Proc 1993 0.80
233 Enhancement of the induction of murine thymic lymphomas by cyclosporine. Transplantation 1986 0.80
234 Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001 0.79
235 Central venulitis in the allograft liver: a clinicopathologic study. Transplantation 1997 0.79
236 Unusual peripheral T cell lymphoma presenting as acute liver failure and reappearing in the liver allograft. Transplantation 2000 0.79
237 Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci 1992 0.79
238 Detection of pancreatic islet tissue following islet allotransplantation in man. Transplantation 1991 0.79
239 Transplantation unresponsiveness induced by liver allografts in mouse strains with various histocompatibility disparities. Transplant Proc 1992 0.79
240 Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc 1997 0.79
241 Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation. Transplant Proc 1995 0.79
242 Destruction of endothelial cells by humoral factors obtained from recipients of xenografts. Transplant Proc 1994 0.79
243 Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol 1996 0.79
244 Allograft and xenograft acceptance under FK-506 and other immunosuppressant treatment. Ann N Y Acad Sci 1993 0.79
245 Isolation and characterization of a human hepatic epithelial-like cell line (AKN-1) from a normal liver. In Vitro Cell Dev Biol Anim 1999 0.79
246 Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. Transplant Proc 1993 0.79
247 Prospective evaluation of endoscopy in acute cellular rejection and cytomegalovirus infection. Transplant Proc 1996 0.79
248 Propagation of dendritic cell progenitors from mouse liver and their in vivo migration to T-dependent areas of allogeneic lymphoid tissue. Transplant Proc 1994 0.79
249 Reversal of graft-versus-host disease with infusion of autologous bone marrow. Cell Transplant 1994 0.79
250 Mechanisms of hamster kidney graft rejection in the rat. Transplant Proc 1994 0.79
251 Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. Transplant Proc 1991 0.79
252 Functional analysis of hamster kidney xenografts in the rat: possible functional incompatibility and adaptation of hamster kidney grafts in a xenogenic rat environment. Transplant Proc 1996 0.78
253 Significance of tubulitis in chronic allograft nephropathy: a clinicopathologic study. Clin Transplant 1997 0.78
254 Lipid peroxidation of liver microsome membranes induced by choline-deficient diets and its relationship to the diet-induced promotion of the induction of gamma-glutamyltranspeptidase-positive foci. Cancer Res 1985 0.78
255 Will xenotransplantation ever be feasible? J Am Coll Surg 1998 0.78
256 The potential role of cytokines in the pathogenesis of Epstein-Barr virus associated post-transplant lymphoproliferative disease. Leuk Lymphoma 1994 0.78
257 Frequency and severity of HCV infection following orthotopic liver transplantation. Effect of donor and recipient serology for HCV using a second generation ELISA test. J Hepatol 1993 0.78
258 The two-way paradigm of transplantation immunology. Clin Immunol Immunopathol 1996 0.78
259 Adenovirus hepatitis in the adult allograft liver. Transplantation 1997 0.78
260 Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. Transplantation 1996 0.78
261 Hematopoietic reconstitution by transplanted grafts in lethally irradiated recipients. Transplant Proc 1997 0.78
262 Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: effect of viral hepatitis D. Liver Transpl 2000 0.78
263 Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin Transpl 1994 0.78
264 Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. Transplant Proc 1996 0.78
265 Propagation of cells expressing donor phenotype (MHC class I, II and Y-chromosome) from the bone marrow of murine liver allograft recipients in response to GM-CSF in vitro. Transplant Proc 1995 0.78
266 Identification of donor hematopoietic progenitor cells after allogeneic liver transplantation. Transplant Proc 1997 0.77
267 FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 1993 0.77
268 Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. Transplant Proc 1995 0.77
269 Report of the Third Banff Conference on Allograft Pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 1996 0.77
270 Dendritic cells/chimerism/alleviation of chronic allograft rejection. J Leukoc Biol 1999 0.77
271 Postinfantile giant cell hepatitis associated with anti-M2 mitochondrial antibodies. Gastroenterology 1994 0.77
272 Exposure to type-I collagen induces maturation of mouse liver dendritic cell progenitors. Adv Exp Med Biol 1995 0.77
273 Hepatitis C virus infection in liver allografts. Pathol Annu 1995 0.77
274 Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. J Clin Invest 1996 0.77
275 Cellular composition of islet cell suspensions for transplantation. Transplant Proc 1992 0.77
276 Pretreatment of recipients (nude rat) with donor antigens leads to prolonged survival of hamster heart xenografts. Transplant Proc 1996 0.77
277 Liver transplantation: a 31-year perspective. Part II. Curr Probl Surg 1990 0.77
278 Inhibition of free radical generation and improved survival by protection of the hepatic microvascular endothelium by targeted erythrocytes in orthotopic rat liver transplantation. Transplantation 1990 0.77
279 Liver graft induced donor specific unresponsiveness without class I and/or class II antigen differences. Transplant Proc 1993 0.76
280 Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. Transplant Proc 1997 0.76
281 Evidence that canine pancreatic islets promote the survival of human hepatocytes in nude mice. Transplantation 1991 0.76
282 Evidence for heat shock protein immunity in a rat cardiac allograft model of chronic rejection. Transplantation 1999 0.76
283 Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. Transplant Proc 1993 0.76
284 Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. Transplant Proc 1994 0.76
285 Persistence of donor-reactive T cells after liver transplantation-induced tolerance in mice. Transplant Proc 1993 0.76
286 The effect of splenectomy on cardiac and liver xenografts in the nude rat. Transplant Proc 1994 0.76
287 Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999 0.76
288 A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment. Exp Hematol 1998 0.76
289 Human islet allotransplantation in 18 diabetic patients. Transplant Proc 1992 0.76
290 Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention. Graft (Georget Tex) 1998 0.76
291 Ischemic cholangitis. Mayo Clin Proc 1992 0.76
292 Xenobiotics, chimerism and the induction of tolerance following organ transplantation. Ther Immunol 1994 0.76
293 Chimerism after organ transplantation. Curr Opin Nephrol Hypertens 1997 0.76
294 Outcome of human islet isolation and allotransplantation in 20 consecutive cases. Diabetes Nutr Metab 1992 0.75
295 Preformed antibodies in sensitized recipients: effect of immunoglobulin titer, class, and specificity on liver and heart allografts. Transplant Proc 1993 0.75
296 Human islet isolation and transplantation in chronic pancreatitis using the automated method. Transplant Proc 1992 0.75
297 Allospecificity of liver allograft-derived lymphocytes and correlation with clinicopathologic findings. Transplant Proc 1988 0.75
298 Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant 1997 0.75
299 Indefinite survival of rat islet allografts following infusion of donor bone marrow without cytoablation. Cell Transplant 1996 0.75
300 Chimerism, graft-vs-host disease, rejection, and their association with reciprocal donor-host immune reactions after cell, organ, and composite tissue transplantation. Transplant Proc 1997 0.75
301 Detection of intrahepatic human islets following combined liver-islet allotransplantation. Pancreas 1992 0.75
302 Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis 1998 0.75
303 Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. Transplant Proc 1994 0.75
304 Hepatitis B after liver transplantation: new names for unusual presentations. Gastroenterology 1992 0.75
305 Intrapancreatic islet transplantation as a potential solution to chronic failure of intraportal islet grafts. Transplant Proc 1993 0.75
306 Cytokine messenger RNA profiles in hamster-to-rat liver xenografts. Transplant Proc 1993 0.75
307 Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc 1997 0.75
308 Histologic finding of pancreatic islet tissue following intraportal human islet allotransplantation. Transplant Proc 1992 0.75
309 In vitro assessment of FK 506 immunosuppressive activity in transplant patients. Transplant Proc 1991 0.75
310 Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. Transplantation 1992 0.75
311 The use of MHC class I or class II "knock out" mice to investigate the role of these antigens in allosensitization. Transplant Proc 1995 0.75
312 The role of antibodies in liver graft-induced tolerance in mice: passive transfer of serum and effect of recipient B-cell depletion. Transplant Proc 1995 0.75
313 Frozen section of liver biopsy for the evaluation of liver allografts. Transplant Proc 1990 0.75
314 Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc 1996 0.75
315 Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. Transplantation 1996 0.75
316 Mucosal recipient-type mononuclear repopulation and low-grade chronic rejection occur simultaneously in indefinitely surviving recipients of small bowel allografts. Transpl Int 1994 0.75
317 Matching and the black recipient. Transplant Proc 1993 0.75
318 Rejection and hepatitis in liver transplants. Transplantation 1994 0.75
319 The changing immunology of organ transplantation. Hosp Pract (1995) 1995 0.75
320 Functional analysis of graft lamina propria associated lymphocytes from a recipient of a human cadaveric small bowel allograft primarily immunosuppressed with FK 506. Transplant Proc 1991 0.75
321 Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation: inhibition of humoral response and acceptance of donor organs. Transplant Proc 1996 0.75
322 Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. Transplant Proc 1999 0.75
323 Characteristics of graft-versus-host disease after Lewis-to-brown-Norway rat small bowel transplantation. Transplant Proc 1994 0.75
324 Immunoreactivity of T lymphocytes propagated from biopsies of human cadaveric small intestine allografts: a serial study of four patients. Transplant Proc 1992 0.75
325 Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. Transplant Proc 1995 0.75
326 Epstein-Barr virus-encoded RNA expression as a risk factor for the development of posttransplantation lymphoproliferative disease. Hepatology 1995 0.75
327 Histopathologic changes of antibody-mediated small bowel graft rejection in blood-transfused recipients. Transplant Proc 1996 0.75
328 Complement activation correlates with graft damage in baboon-to-human liver xenotransplantation. Transplant Proc 1994 0.75
329 Cytokine profile in graft-versus-host disease after small bowel transplantation. Transplant Proc 1996 0.75
330 The bidirectional paradigm of transplant immunology. Ann N Y Acad Sci 1995 0.75
331 Donor-recipient microchimerism and tolerance induction. Transplantation 1996 0.75
332 Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. Transplant Proc 1996 0.75
333 Hepatitis viral markers in patients undergoing primary liver transplants. Dig Dis Sci 1993 0.75
334 Influence of donor-recipient strain combinations on immunologic responses after allogeneic rat small bowel transplantation. Transplant Proc 1994 0.75
335 Chimerism and xenotransplantation. New concepts. Surg Clin North Am 1999 0.75
336 FK 506, cardiac transplantation, and graft-vessel disease. Lancet 1992 0.75
337 Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease. Transplantation 1998 0.75
338 Long-term survival of heart and liver xenografts with splenectomy and FK 506. Transplant Proc 1993 0.75
339 Metabolic changes in the recipient after successful liver xenotransplantation in the rat. Transplant Proc 1994 0.75
340 Survival of human hepatocellular aggregates in athymic mice. Transplant Proc 1992 0.75
341 Capillarization of the hepatic sinusoid in failed liver grafts. Transplant Proc 1993 0.75
342 Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. Transplant Proc 1994 0.75
343 Role of HLA in intragraft cellular immunity in human liver transplantation. Transplant Proc 1988 0.75
344 Subcutaneous implantation of human post-transplant lymphoproliferative disease lesions in SCID mice. Hematol Oncol 1997 0.75
345 Cardiac transplantation at the University of Pittsburgh: 1994 update. Clin Transpl 1994 0.75
346 The protection from humoral rejection given by a liver xenograft is species-specific and non-MHC restricted. Transplant Proc 1995 0.75
347 Early clinical and histologic viability of human liver-small intestinal allografts after implantation. Clin Transplant 1994 0.75
348 Histologic evaluation of preservation injury in clinical small bowel transplantation. Transplant Proc 1994 0.75
349 Histologic spectrum of acute cellular rejection in human intestinal allografts. Transplant Proc 1996 0.75
350 Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Trends Pharmacol Sci 1993 0.75
351 Periportal low-attenuation areas on CT: value as evidence of liver transplant rejection. AJR Am J Roentgenol 1989 0.75
352 Liver allograft pathology in liver/small bowel or multivisceral recipients. Mod Pathol 1996 0.75
353 Renal allograft involvement by Epstein-Barr virus associated post-transplant lymphoproliferative disease. Am J Surg Pathol 1996 0.75
354 Digital pathology services in acute surgical situations. Br J Surg 2014 0.75
355 Intrahepatic cholangiographic abnormalities in liver transplants: correlation with biopsy evidence of rejection and other disorders. AJR Am J Roentgenol 1989 0.75
356 Propagation and characterization of lymphocytes infiltrating livers of patients with primary biliary cirrhosis and autoimmune hepatitis. Hum Immunol 1990 0.75
357 [Clinical experience with FK 506]. Presse Med 1991 0.75
358 Neonatal bone fragments for the induction of xenograft acceptance: transplantation of xenogeneic hematopoietic stem cells and species-specific microenvironment for hematopoiesis. Transplant Proc 1997 0.75
359 Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. Transplant Proc 1996 0.75
360 FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. Transplant Proc 1994 0.75
361 Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. Transplant Proc 1994 0.75
362 Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. Transplant Proc 1991 0.75
363 Morphologic and immunophenotypic characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease. In Vitro Cell Dev Biol Anim 1994 0.75
364 Migratory nonparenchymal cells after organ allotransplantation: with particular reference to chimerism and the liver. Prog Liver Dis 1994 0.75
365 Extramedullary hematopoiesis in the allograft liver. Mod Pathol 1995 0.75
366 The pathology of liver transplantation. Prog Liver Dis 1990 0.75
367 Histopathology of renal posttransplant lymphoproliferation: comparison with rejection using the Banff schema. Am J Kidney Dis 1996 0.75
368 Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. Transplant Proc 2000 0.75
369 Intrahepatic bile duct strictures in a liver allograft recipient mimicking recurrent primary sclerosing cholangitis. Follow-up of a case report. Transpl Int 1991 0.75
370 Liver allograft pathology in liver/small bowel or multivisceral recipients. Transplant Proc 1996 0.75
371 Detection of cytomegalovirus in formalin-fixed paraffin-embedded donor, native and allograft liver tissue using a multiplex polymerase chain reaction-liquid hybridization assay. Mod Pathol 1994 0.75
372 Mechanisms of protection from humoral rejection by a xenografted liver. Transplant Proc 1995 0.75
373 A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Transplant Proc 2002 0.75
374 A simplified method for growing dendritic cells from rat bone marrow. Adv Exp Med Biol 1995 0.75
375 Allograft liver biopsy in patients with Epstein-Barr virus-associated posttransplant lymphoproliferative disease. Am J Surg Pathol 2001 0.75
376 Bile duct hemorrhage: a biopsy finding after cholangiography or biliary tree manipulation. Liver 1992 0.75